Aurobindo Pharma gained 4.91% to Rs 538.90 at 10:00 IST on BSE after the company reported Q4 results.
The result was announced after market hours yesterday, 29 May 2017.The stock had fallen 3.67% to Rs 513.70 yesterday, 29 May 2017, ahead of its Q4 results.
Meanwhile, the S&P BSE Sensex was up 88.74 points, or 0.29%, to 31,197.66.
Higher than usual volumes were witnessed on the counter. On the BSE, 4.38 lakh shares were traded in the counter so far, compared with average daily volumes of 2.57 lakh shares in the past one quarter. The stock had hit a high of Rs 547.45 and a low of Rs 506 so far during the day.
The stock had hit a record high of Rs 895 on 6 October 2016. The stock had hit a 52-week low of Rs 504 yesterday. 29 May 2017. The stock had underperformed the market over the past one month till 29 May 2017, falling 15.24% compared with the 3.98% gains in the Sensex. The scrip had also underperformed the market in past one quarter, falling 24.14% as against Sensex's 8.23% gains.
The large-cap company has equity capital of Rs 58.59 crore. Face value per share is Re 1.
More From This Section
Aurobindo Pharma's consolidated net profit fell 3.9% to Rs 532.90 crore on 2.8% decline in operating income to Rs 3641.60 crore in Q4 March 2017 over Q4 March 2016.
The company's board of Directors approved second interim dividend of Rs 1.25 per share for the year ended 31 March 2017 (FY 2017).
EBITDA (earnings before interest, taxes, depreciation and amortization) before forex and other income fell 16.74% to Rs 721 crore in Q4 March 2017 over Q4 March 2016. EBITDA was impacted by one-time inventory write-off and other exceptional items. EBITDA margin fell to 19.8% in Q4 March 2017 from 23.1% in Q4 March 2016.
The board of directors decided not to transfer its injectable unit on a going concern basis comprising assets and liabilities pertaining to the unit to its wholly owned subsidiary namely, Curepro Parenterals, considering the expansion and growth plans of the company. The decision is subject to the approval of appropriate authorities including High Court or Tribunal as the case may be.
The board of directors on 12 September 2013 had approved the transfer of the unit. The same was subject to requisite consents, approvals or permissions of the statutory or regulatory authorities. Pending such approvals, no effect of this scheme was given till date.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients.
Powered by Capital Market - Live News